The burgeoning market for obesity treatments, propelled recently by the widespread adoption of GLP-1 receptor agonists, stands at a critical…
Read More
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
The burgeoning market for obesity treatments, now valued at an astonishing $1 trillion, stands at a pivotal juncture. While GLP-1…
Read More
CagriSema Surpasses Semaglutide in Efficacy and Safety for Obesity and Overweight Management, According to New Meta-Analysis
New Orleans, LA – A groundbreaking Bayesian network meta-analysis presented at the American College of Cardiology (ACC) 75th Annual Scientific…
Read More
Eli Lilly’s Foundayo Secures FDA Approval, Challenging Novo Nordisk’s Oral Obesity Drug Dominance
The United States Food and Drug Administration (FDA) has granted approval to Eli Lilly and Company’s novel oral glucagon-like peptide-1…
Read More
OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders and pioneering a new frontier in obesity therapeutics
OrsoBio, a dynamic biotech enterprise dedicated to advancing novel therapies for obesity and a spectrum of obesity-related metabolic disorders, is…
Read MoreYOU MAY HAVE MISSED
